The Stelara (Ustekinumab) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global market size for Stelara (Ustekinumab) has seen robust growth in the past years. It is projected to increase from $11,177.34 million in 2024 to $11,850.79 million in 2025, indicating a compound annual growth rate (CAGR) of 6.0%.
By 2029, the Stelara (Ustekinumab) global market is projected to be worth $14,768.48 million, growing at a compound annual growth rate (CAGR) of 5.7%.
Download Your Free Sample of the 2025 Stelara (Ustekinumab) Market Report and Uncover Key Trends Now!The key drivers in the stelara ustekinumab market are:
• Increase in the number of psoriasis patients globally
• Advances in diagnostic techniques for early detection of psoriasis
• Enhancement in quality of life through effective management and treatment of psoriasis symptoms with Stelara
• Impact of environmental factors and genetic predisposition on the rise of psoriasis cases.
The stelara (ustekinumab) market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications
2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Pediatric, Adult, Geriatric
The key trends in the stelara ustekinumab market are:
• The development of long-acting formulations is a key trend.
• AI integration in treatment monitoring is on the rise.
• Digital health platforms for patient management are becoming more prevalent.
• There is an increased focus on raising awareness for rare diseases.
Major players in the stelara ustekinumab market are:
• Johnson & Johnson
The North America region leads the global Stelara (Ustekinumab) market as per the 2025 report.